Related Articles
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)